Efficacy of Janus Kinase Inhibitors in Alopecia in Jordanian Patients: A Retrospective Cohort Study

This retrospective cohort study assessed the efficacy of JAK inhibitors, tofacitinib and baricitinib, in 57 Jordanian patients with alopecia areata (AA) using the SALT score. Both drugs resulted in significant hair regrowth, with baricitinib showing greater improvement in SALT scores than tofacitinib, especially from six to 12 months (92.77% vs. 82.93%; p = 0.030). Baricitinib also showed higher, though not statistically significant, improvements in eyebrow and eyelash regrowth. The study suggests baricitinib may provide a more substantial late-stage response in treating AA, but acknowledges the need for further research due to its retrospective nature and small sample size.